FDA clearance of IND application for VO659 with plans to initiate US-based clinical trial later this year New data highlight […]
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseases VO659 was designed to preferentially
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer.
BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day,
Leiden, The Netherlands, 29 July 2021 – VICO Therapeutics, a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the
Leiden, The Netherlands, 29 June 2021 – VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA
As a friend of Rare Disease Day and to show our support in their continuous quest to raise awareness amongst
Leadership
Micah Mackison
Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.
Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.
